Direxion Daily S&P Biotech Bear 3X Shares (LABD) seeks to deliver three times the inverse daily performance of the S&P Biotechnology Select Industry Index, which tracks U.S. biotechnology companies developing drugs, medical devices, and diagnostic products. This leveraged inverse ETF profits when biotech stocks decline.
How It Works
LABD uses derivatives including swaps and futures contracts to achieve -300% daily exposure to its benchmark index. The fund rebalances daily to maintain the 3x inverse leverage ratio, meaning it resets its exposure each trading day. As an inverse ETF, it moves opposite to biotech stocks—when the index falls 1%, LABD aims to gain 3%. Holdings consist primarily of derivative instruments rather than actual biotech stocks.
Key Features
- Provides 3x amplified gains when biotech sector declines, offering hedging tool for biotech-heavy portfolios
- Daily rebalancing maintains consistent -300% exposure regardless of market movements or volatility spikes
- Targets specific biotechnology subsector rather than broader healthcare, allowing precise sector betting
Risks
- This ETF can lose value rapidly if biotech stocks rise, with potential for 30-60% daily losses during strong biotech rallies
- Daily reset causes compounding decay—if biotech drops 10% then rises 10%, LABD does not return to break-even due to leverage mathematics
- Biotech sector volatility amplifies losses, as individual drug trial failures or FDA approvals can trigger massive single-day moves exceeding 20%
Who Should Own This
Suitable only for sophisticated traders with high risk tolerance seeking short-term (hours to days) hedging or speculation on biotech sector declines. Requires active daily monitoring and should represent less than 5% of portfolio. Not appropriate for buy-and-hold investors due to daily reset compounding effects that erode returns over time.